Diagnosis and Treatment of Anaplastic Thyroid Carcinoma
Patorn Piromchai, Teeraporn Ratanaanekchai, Pornthep Kasemsiri
DOI: 10.4236/ijcm.2012.31016   PDF    HTML   XML   4,222 Downloads   8,760 Views   Citations


Anaplastic thyroid carcinoma (ATC) is a poorly differentiated thyroid cancer. It cannot uptake iodine or synthesis thyroglobulin. The incidence is low; about 2% - 5% of thyroid cancer. The peak age incidence is 60 - 70 years and it is more common in females (55% - 77% of all patients). In recent years, the incidence has declined; however, it may be higher in areas of endemic goiter. ATC may occur with a coexisting carcinoma and may represent transformation of a well-differentiated thyroid cancer. Patients typically present with a rapidly growing anterior neck mass and aggressive symptoms. The most reliable tool in detecting thyroid malignancies is fine-needle aspiration cytology (FNAC). Sensitivity of FNAC for thyroid malignancy ranged from 61% to 97.7%. Fine-needle aspiration can diagnose ATC by the demonstration of spindled or giant cells, bizarre neoplastic cells that may be multinucleated, or atypical cells with high mitotic activity. A syncytial pattern is the predominant cellular pattern of anaplastic thyroid carcinoma. Other laboratory tests, including tumor markers (cytokeratin, vimentin, and carcinoembryogenic antigen) are helpful in diagnosis and follow-up of the patients. Multimodality therapy (surgery, external beam radiation, and chemotherapy) is the recommended treatment and it seems to have slightly improved outcomes. The prognosis is not as bad in younger patients with smaller tumors. The most common cause of death is lung metastasis. The mean survival time is less than 6 months from the time of diagnosis. The prompt diagnosis and aggressive treatment are essential modality to achieve optimal outcomes.

Share and Cite:

P. Piromchai, T. Ratanaanekchai and P. Kasemsiri, "Diagnosis and Treatment of Anaplastic Thyroid Carcinoma," International Journal of Clinical Medicine, Vol. 3 No. 1, 2012, pp. 69-73. doi: 10.4236/ijcm.2012.31016.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] S. Agrawal, R. S. Rao, D. M. Parikh, H. K. Parikh, A. M. Borges and M. B. Sampat, “Histologic Trends in Thyroid Cancer 1969-1993: A Clinico-Pathologic Analysis of the Relative Proportion of Anaplastic Carcinoma of the Thyroid,” Journal of Surgical Oncology, Vol. 63, No. 4, 1996, pp. 251-255. doi:10.1002/(SICI)1096-9098(199612)63:4<251::AID-JSO7>3.0.CO;2-B
[2] P. Lampertico, “Anaplastic (Sarcomatoid) Carcinoma of the Thyroid Gland,” Seminars in Diagnostic Pathology, Vol. 10, No. 2, 1993, pp. 159-168.
[3] R. K. Tan, R. K. Finley III, D. Driscoll, V. Bakamjian, W. L. Hicks Jr. and D. P. Shedd, “Anaplastic Carcinoma of the Thyroid: A 24-Year Experience,” Head & Neck, Vol. 17, No. 1, 1995, pp. 41-48. doi:10.1002/hed.2880170109
[4] M. W. Myskow, A. S. Krajewski, A. E. Dewar, E. P. Millar, K. McLaren and J. W. Fabre, “The Role of Immunoperoxidase Techniques on Paraffin Embedded Tissue in Determining the Histogenesis of Undifferentiated Thyroid Neoplasms,” Clinocal Endocrinology, Vol. 24, No. 3, 1986, pp. 335-341. doi:10.1111/j.1365-2265.1986.tb03275.x
[5] A. Tobler, R. Maurer and C. E. Hedinger, “Undifferentiated Thyroid Tumors of Diffuse Small Cell Type. Histological and Immunohistochemical Evidence for Their Lymphomatous Nature,” Virchows Archiv, Vol. 404, No. 2, 1984, pp. 117-126. doi:10.1007/BF00704057
[6] T. Holting, P. Moller, C. Tschahargane, H. Meybier, H. Buhr and C. Herfarth, “Immunohistochemical Reclassification of Anaplastic Carcinoma Reveals Small and Giant cell Lymphoma,” World Journal of Surgery, Vol. 14, No. 3, 1990, pp. 291-295. doi:10.1007/BF01658506
[7] J. G. Demeter, S. A. De Jong, A. M. Lawrence and E. Paloyan, “Anaplastic Thyroid Carcinoma: Risk Factors and Outcome,” Surgery, Vol. 110, No. 3, 1991, pp. 956-961.
[8] C. Are and A. R. Shaha, “Anaplastic Thyroid Carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment Approaches,” Annals of Surgical Oncology, Vol. 13, No. 4, 2006, pp. 453-464. doi:10.1245/ASO.2006.05.042
[9] S. M. Wiseman, H. Masoudi, P. Niblock, D. Turbin, A. Rajput, J. Hay, S. Bugis, D. Filipenko, D. Huntsman and B. Gilks, “Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment,” Annals of Surgical Oncology, Vol. 14, No. 2, 2007, pp. 719-729. doi:10.1245/s10434-006-9178-6
[10] H. S. Chang, K. H. Nam, W. Y. Chung and C. S. Park, “Anaplastic Thyroid Carcinoma: A Therapeutic Dilemma,” Yonsei Medical Journal, Vol. 46, No. 6, 2005, pp. 759-764. doi:10.3349/ymj.2005.46.6.759
[11] K. B. Ain, “Anaplastic Thyroid Carcinoma: A Therapeutic Challenge,” Seminars in Surgical Oncology, Vol. 16, No. 1, 1999, pp. 64-69. doi:10.1002/(SICI)1098-2388(199901/02)16:1<64::AID-SSU10>3.0.CO;2-U
[12] J. Shvero, R. Gal, I. Avidor, T. Hadar and E. Kessler, “Anaplastic Thyroid Carcinoma. A Clinical, Histologic, and Immunohistochemical Study,” Cancer, Vol. 62, No. 21, 1988, pp. 319-325. doi:10.1002/1097-0142(19880715)62:2<319::AID-CNCR2820620216>3.0.CO;2-T
[13] D. Giuffrida and H. Gharib, “Anaplastic Thyroid Carcinoma: Current Diagnosis and Treatment,” Annals of Oncology, Vol. 11, No. 9, 2000, pp. 1083-1089. doi:10.1023/A:1008322002520
[14] B. McIver, I. D. Hay, D. F. Giuffrida, C. E. Dvorak, C. S. Grant, G. B. Thompson, J. A. van Heerden and J. R. Goellner, “Anaplastic Thyroid Carcinoma: A 50-Year Experience at a Single Institution,” Surgery, Vol. 130, No. 6, 2001, pp. 1028-1034. doi:10.1067/msy.2001.118266
[15] H. L. Evans, “Columnar-Cell Carcinoma of the Thyroid. A Report of Two Cases of an Aggressive Variant of Thyroid Carcinoma,” American Journal of Clinical Pathology, Vol. 85, No. 1, 1986, pp. 77-80.
[16] M. Sobrinho-Simoes, J. M. Nesland and J. V. Johannessen, “Columnar-Cell Carcinoma. Another Variant of Poorly Differentiated Carcinoma of the Thyroid,” American Journal of Clinical Pathology, Vol. 89, No. 2, 1988, pp. 264-267.
[17] M. Papotti, F. Botto Micca, A. Favero, N. Palestini and G. Bussolati, “Poorly Differentiated Thyroid Carcinomas with Primordial Cell Component. A Group of Aggressive Lesions Sharing Insular, Trabecular, and Solid Patterns,” American Journal of Surgical Pathology, Vol. 17, No. 3, 1993, pp. 291-301. doi:10.1097/00000478-199303000-00010
[18] N. G. Ordonez, A. K. El-Naggar, R. C. Hickey and N. A. Samaan, “Anaplastic Thyroid Carcinoma. Immunocytochemical Study of 32 Cases,” American Journal of Clinical Pathology, Vol. 96, 1991, pp. 15-24.
[19] F. Pacini, M. G. Castagna, L. Brilli and G. Pentheroudakis, “Thyroid Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up,” Annals of Oncology, Vol. 21, Supplement 5, 2010, pp. 214-219. doi:10.1093/annonc/mdq190
[20] G. L. La Rosa, A. Belfiore, D. Giuffrida, C. Sicurella, O. Ippolito, G. Russo and R. Vigneri, “Evaluation of the Fine Needle Aspiration Biopsy in the Preoperative Selection of Cold Thyroid Nodules,” Cancer, Vol. 67, No. 8, 1991, pp. 2137-2141. doi:10.1002/1097-0142(19910415)67:8<2137::AID-CNCR2820670822>3.0.CO;2-Y
[21] D. C. Howlett, B. Harper, M. Quante, A. Berresford, M. Morley, J. Grant, K. Ramesar and S. Barnes, “Diagnostic Adequacy and Accuracy of Fine Needle Aspiration Cytology in Neck Lump Assessment: Results from a Regional Cancer Network over a One Year Period,” The Journal of Laryngology & Otology, Vol. 121, No. 6, 2007, pp. 571-579. doi:10.1017/S0022215106004944
[22] Y. Bajaj, M. De and A. Thompson, “Fine Needle Aspiration Cytology in Diagnosis and Management of Thyroid Disease,” The Journal of Laryngology & Otology, Vol. 120, No. 6, 2006, pp. 467-469. doi:10.1017/S0022215106000703
[23] W. J. Tan, K. Sanghvi, K. H. Liau and C. H. Low, “An Audit Study of the Sensitivity and Specificity of Ultrasound, Fine Needle Aspiration Cytology and Frozen Section in the Evaluation of Thyroid Malignancies in a Tertiary Institution,” Annals of the Academy of Medical Singapore, Vol. 39, No. 5, 2010, pp. 359-362.
[24] B. P. Bommanahalli, R. V. Bhat and R. Rupanarayan, “A Cell Pattern Approach to Interpretation of Fine Needle Aspiration Cytology of Thyroid Lesions: A Cyto-Histomorphological Study,” Journal of Cytology, Vol. 27, No. 4, 2010, pp. 127-132. doi:10.4103/0970-9371.73295
[25] A. Yucel, O. Yilmaz, S. Babaoglu, M. Acar and B. Degirmenci, “Sonographic Findings of the Median Nerve and Prevalence of Carpal Tunnel Syndrome in Patients with Parkinson’s Disease,” European Journal of Radiology, Vol. 67, No. 3, 2008, pp. 546-550. doi:10.1016/j.ejrad.2007.08.001
[26] D. D. Pothier and A. A. Narula, “Should We Apply Suction during Fine Needle Cytology of Thyroid Lesions? A Systematic Review and Meta-Analysis,” Annals of Royal College of Surgions of England, Vol. 88, No. 7, 2006, pp. 643-645. doi:10.1308/003588406X149147
[27] S. A. Polyzos and A. D. Anastasilakis, “Clinical Complications Following Thyroid Fine-Needle Biopsy: A Systematic Review,” Clinical Endocrinology, Vol. 71, No. 2, 2009, pp. 157-165. doi:10.1111/j.1365-2265.2009.03522.x
[28] E. Abelardo, M. Jaramillo, E. Sheffield and P. Tierney “Anaplastic Thyroid Carcinoma Implantation after Fine Needle Aspiration Cytology,” The Journal of Laryngology & Otol-ogy, Vol. 121, No. 3, 2007, pp. 268-270. doi:10.1017/S0022215106003264
[29] F. Stacul, M. Bertolotto, F. De Gobbis, L. Calderan, V. Cioffi, A. Romano, F. Zanconati and M. A. Cova, “US, Colour-Doppler US and Fine-Needle Aspiration Biopsy in the Diagnosis of Thyroid Nodules,” Radiologia Medica, Vol. 112, No. 5, 2007, pp. 751-762. doi:10.1007/s11547-007-0178-9
[30] E. Koike, S. Noguchi, H. Yamashita, T. Murakami, A. Ohshima and H. Kawamoto, “Ultrasonographic Characteristics of Thyroid Nodules: Prediction of Malignancy,” Archives of Surgery, Vol. 136, No. 3, 2001, pp. 334-337. doi:10.1001/archsurg.136.3.334
[31] D. S. Cooper, G. M. Doherty, B. R. Haugen, R. T. Kloos, S. L. Lee, S. J. Mandel, E. L. Mazzaferri, B. McIver, S. I. Sherman and R. M. Tuttle, “Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer,” Thyroid, Vol. 16, No. 2, 2006, pp. 109-142. doi:10.1089/thy.2006.16.109
[32] C. Y. Eng, M. S. Quraishi and P. J. Bradley, “Management of Thyroid Nodules in Adult Patients,” Head & Neck Oncology, Vol. 2, 2010, p. 11. doi:10.1186/1758-3284-2-11
[33] T. Poisson, D. Deandreis, S. Leboulleux, F. Bidault, G. Bonniaud, S. Baillot, A. Auperin, A. Al Ghuzlan, J. P. Travagli and J. Lumbroso, et al., “18F-Fluorodeoxyglucose Positron Emission Tomography and Computed Tomography in Anaplastic Thyroid Cancer,” European Journal of Nuclear Medicine and Molecular Imaging, Vol. 37, No. 12, 2010, pp. 2277-2285. doi:10.1007/s00259-010-1570-6
[34] N. Khan, N. Oriuchi, T. Higuchi and K. Endo, “Review of Fluorine-18-2-fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) in the Follow-Up of Medullary and Anaplastic Thyroid Carcinomas,” Cancer Control, Vol. 12, 2005, pp. 254-260.
[35] F. Lumachi, S. Borsato, A. Tregnaghi, F. Marino, F. Polistina, S. M. Basso, H. Koussis, U. Basso and A. Fassina, “FNA Cytology and Frozen Section Examination in Patients with Follicular Lesions of the Thyroid Gland,” Anticancer Research, Vol. 29, No. 12, 2009, pp. 5255-5257.
[36] G. F. Huber, P. Dziegielewski, T. W. Matthews, S. J. WarshawskiJ, L. M. Kmet, P. Faris, M. Khalil and J. C. Dort, “Intraoperative Frozen-Section Analysis for Thyroid Nodules: A Step toward Clarity or Confusion?” Arch Otolaryngology Head & Neck Surgery, Vol. 133, No. 9, 2007, pp. 874-881. doi:10.1001/archotol.133.9.874
[37] M. L. Richards, R. Chisholm, J. M. Bruder and W. E. Strodel, “Is Thyroid Frozen Section Too Much for Too Little?” The American Journal of Surgery, Vol. 184, No. 6, 2002, pp. 510-514. doi:10.1016/S0002-9610(02)01074-7
[38] L. A. Boyd, R. C. Earnhardt, J. T. Dunn, H. F. Frierson and J. B. Hanks, “Preoperative Evaluation and Predictive Value of Fine-Needle Aspiration and Frozen Section of Thyroid Nodules,” Journal of the American College of Surgeons, Vol. 187, No. 5, 1998, pp. 494-502. doi:10.1016/S1072-7515(98)00221-X
[39] C. R. McHenry, C. Raeburn, T. Strickland and J. J. Marty, “The Utility of Routine Frozen Section Examination for Intraoperative Diagnosis of Thyroid Cancer,” The American Journal of Surgery, Vol. 172, No. 6, 1996, pp. 658- 661. doi:10.1016/S0002-9610(96)00302-9
[40] R. C. Anton and T. M. Wheeler, “Frozen Section of Thyroid and Parathyroid Specimens,” Archives of Pathology & Laboratory Medicine, Vol. 129, No. 12, 2005, pp. 1575-1584.
[41] Y. S. Venkatesh, N. G. Ordonez, P. N. Schultz, R. C. Hickey, H. Goepfert and N. A. Samaan, “Anaplastic Carcinoma of the Thyroid. A Clinicopathologic Study of 121 Cases,” Cancer, Vol. 66, No. 2, 1990, pp. 321-330. doi:10.1002/1097-0142(19900715)66:2<321::AID-CNCR2820660221>3.0.CO;2-A
[42] P. I. Haigh, “Anaplastic Thyroid Carcinoma,” Current Treatment Options in Oncology, Vol. 1, No. 4, 2000, pp. 353-357. doi:10.1007/s11864-000-0051-8
[43] L. D. Green, L. Mack and J. L. Pasieka, “Anaplastic Thyroid Cancer and Primary Thyroid Lymphoma: A Review of These Rare Thyroid Malignancies,” Journal of Surgical Oncology, Vol. 94, No. 8, 2006, pp. 725-736. doi:10.1002/jso.20691
[44] J. L. Pasieka, “Anaplastic Thyroid Cancer,” Current Treatment Options in Oncology, Vol. 15, No. 1, 2003, pp. 78-83. doi:10.1097/00001622-200301000-00012
[45] D. E. Heron, S. Karimpour and P. W. Grigsby, “Anaplastic Thyroid Carcinoma: Comparison of Conventional Radiotherapy and Hyperfractionation Chemoradiotherapy in Two Groups,” American Journal of Clinical Oncology, Vol. 25, No. 5, 2002, pp. 442-446. doi:10.1097/00000421-200210000-00003
[46] S. Prendiville, K. D. Burman, M. D. Ringel, B. M. Shmookler, Z. E. Deeb, K. Wolfe, N. Azumi, L. Wartofsky and R. B. Sessions, “Tall Cell Variant: An Aggressive Form of Papillary Thyroid Carcinoma,” Otolaryngology Head and Neck Surgery, Vol. 122, No. 3, 2000, pp. 352- 357. doi:10.1016/S0194-5998(00)70047-7
[47] G. Crile Jr., K. I. Pontius and W. A. Hawk, “Factors Influencing the Survival of Patients with Follicular Carcinoma of the Thyroid Gland,” Surgery, Gynecology & Obstetrics, Vol. 160, No. 5, 1985, pp. 409-413.
[48] L. Souhami, W. J. Simpson and J. S. Carruthers, “Malignant Lymphoma of the Thyroid Gland,” International Journal of Radiation Oncology, Vol. 6, No. 9, 1980, pp. 1143-1147. doi:10.1016/0360-3016(80)90166-2
[49] J. S. Burke, J. J. Butler and L. M. Fuller, “Malignant Lymphomas of the Thyroid: A Clinical Pathologic Study of 35 Patients Including Ultrastructural Observations,” Cancer, Vol. 39, No. 4, 1977, pp. 1587-1602. doi:10.1002/1097-0142(197704)39:4<1587::AID-CNCR2820390434>3.0.CO;2-V
[50] J. Hamburger, “Nontoxic Goiter,” Springfield, Illinois, 1973.
[51] L. E. Holm, H. Blomgren and T. Lowhagen, “Cancer Risks in Patients with Chronic Lymphocytic Thyroiditis,” The New England Journal of Medicine, Vol. 312, No. 10, 1985, pp.601-604. doi:10.1056/NEJM198503073121001
[52] E. D. Williams, “Malignant Lymphoma of the Thyroid,” Clinics in Endocrinology and Metabolism, Vol. 10, No. 2, 1981, pp. 379-389. doi:10.1016/S0300-595X(81)80029-1
[53] R. G. Watson, M. D. Brennan, J. R. Goellner, J. A. van Heerden, W. M. McConahey and W. F. Taylor, “Invasive Hurthle Cell Carcinoma of the Thyroid: Natural History and Management,” Mayo Clinic Proceedings, Vol. 59, No. 12, 1984, pp. 851-855.
[54] Y. Kitamura, K. Shimizu, M. Nagahama, K. Sugino, O. Ozaki, T. Mimura, K. Ito and S. Tanaka, “Immediate Causes of Death in Thyroid Carcinoma: Clinicopathological Analysis of 161 Fatal Cases,” Journal of Clinical Endocrinology & Metabolism, Vol. 84, No. 11, 1999, pp. 4043-4049. doi:10.1210/jc.84.11.4043
[55] R. C. Smallridge and J. A. Copland, “Anaplastic Thyroid Carcinoma: Pathogenesis and Emerging Therapies,” Clinical Oncology, Vol. 22, No. 6, 2010, pp. 486-497. doi:10.1016/j.clon.2010.03.013
[56] T. Yau, C. Y. Lo, R. J. Epstein, A. K. Lam, K. Y. Wan and B. H. Lang, “Treatment Outcomes in Anaplastic Thyroid Carcinoma: Survival Improvement in Young Patients with Localized Disease Treated by Combination of Surgery and Radiotherapy,” Annals of Surgical Oncology, Vol. 15, No. 9, 2008, pp. 2500-2505. doi:10.1245/s10434-008-0005-0
[57] J. P Pierie, A. Muzikansky, R. D. Gaz, W. C. Faquin and M. J. Ott, “The Effect of Surgery and Radiotherapy on Outcome of Anaplastic Thyroid Carcinoma,” Annals of Surgical Oncology, Vol. 9, No. 1, 2002, pp. 57-64. doi:10.1245/aso.2002.9.1.57
[58] N. Besic, M. Hocevar, J. Zgajnar, A. Pogacnik, S. Grazio-Frkovic and M. Auersperg, “Prognostic Factors in Anaplastic Carcinoma of the Thyroid—A Multivariate Survival Analysis of 188 Patients,” Langenbecks Archives of Surgery, Vol. 390, No. 3, 2005, pp. 203-208. doi:10.1007/s00423-004-0524-5
[59] T. Kobayashi, H. Asakawa, K. Umeshita, T. Takeda, H. Maruyama, F. Matsuzuka and M. Monden, “Treatment of 37 Patients with Anaplastic Carcinoma of the Thyroid,” Head & Neck, Vol. 18, No. 1, 1996, pp. 36-41. doi:10.1002/(SICI)1097-0347(199601/02)18:1<36::AID-HED5>3.0.CO;2-#

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.